Karyopharm Therapeut (KPTI) 7.51 $KPTI Karyopharm

New Post Public Reply Private Reply Replies (0) Message Board

Jun 24, 2016 at 2:19 PM

Karyopharm Therapeut (KPTI) 7.51 $KPTI

Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274
GlobeNewswire - Wed Jun 22, 6:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in a Phase 1 clinical trial evaluating KPT-9274, an oral, first-in-class, dual-acting p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, in patients with advanced solid malignancies (including sarcoma, colon and lung cancer) or non-Hodgkin's lymphoma (NHL) whose disease has relapsed after standard therapy(s) (NCT02702492).
KPTI: 7.51 (-0.52)

Karyopharm Outlines Key Selinexor Clinical Development Achievements
GlobeNewswire - Thu Jun 16, 6:30AM CDT
- Enrollment Complete in Phase 2b STORM Clinical Trial in Multiple Myeloma -
KPTI: 7.51 (-0.52)

Karyopharm to Present at the 2016 JMP Securities Life Science Conference
GlobeNewswire - Wed Jun 15, 6:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 2:00 p.m. E.T. The conference will be held at the St. Regis Hotel in New York.
KPTI: 7.51 (-0.52)

Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting
GlobeNewswire - Fri Jun 10, 6:30AM CDT
- Updated Clinical Data Shows High Response Rates When Selinexor Is Combined with Standard of Care Agents in Heavily Pretreated Patients with Multiple Myeloma -
KPTI: 7.51 (-0.52)

Karyopharm to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Chief Financial Officer of Karyopharm, is scheduled to present at the upcoming Jefferies 2016 Healthcare Conference in New York City on Wednesday, June 8, 2016 at 3:00 p.m. ET.
KPTI: 7.51 (-0.52)

Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting
GlobeNewswire - Thu May 19, 6:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that an abstract describing preliminary activity of selinexor (KPT-330) and dexamethasone in combination with bortezomib (Velcade(R)), pomalidomide (Pomalyst(R)), or lenalidomide (Revlimid(R)) for the treatment of relapsed/refractory multiple myeloma (MM) (the STOMP study) has been accepted for presentation at the 21 Congress of the European Hematology Association (EHA) held June 9-12, 2016 in Copenhagen, Denmark. The abstract describes preliminary Phase 1b data in which responses were observed with selinexor, Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export / SINE(TM) compound that inhibits exportin 1 (XPO1), and dexamethasone in combination with standard of care MM therapies in patients with heavily pretreated MM. Updated and detailed results from the study will be presented at the conference.
KPTI: 7.51 (-0.52)

Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Wed May 18, 4:40PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three abstracts involving selinexor (KPT-330), the Company's lead product candidate selinexor in development for hematological malignancies and solid tumors, have been selected for two poster presentations and one poster discussion at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7 in Chicago. Updated and detailed results from these studies will be presented at the conference. The abstracts, which represent both company- and investigator-sponsored clinical studies, describe data related to selinexor, Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export / SINE(TM) compound that inhibits exportin 1 (XPO1). Posters to be presented include a Phase 2 clinical update with single-agent selinexor in recurrent glioblastoma, Phase 2 study design of single-agent selinexor in advanced liposarcoma and Phase 1 data for selinexor in multiple myeloma in combination with liposomal doxorubicin and dexamethasone.
KPTI: 7.51 (-0.52)

Karyopharm Therapeutics posts 1Q loss
Automated Insights - Mon May 09, 6:47AM CDT
NEWTON, Mass. (AP) _ Karyopharm Therapeutics Inc. (KPTI) on Monday reported a loss of $27.1 million in its first quarter.
KPTI: 7.51 (-0.52)

Karyopharm Reports First Quarter 2016 Financial Results and Highlights Recent Progress
GlobeNewswire - Mon May 09, 6:30AM CDT
Phase 2/3 SEAL Clinical Trial Initiated with Selinexor for Treatment of Liposarcoma
KPTI: 7.51 (-0.52)

Why Earnings Season Could Be Great for Karyopharm Therapeutics (KPTI)
Zacks Equity Research - Zacks Investment Research - Fri May 06, 7:54AM CDT
Karyopharm Therapeutics (KPTI) looks like an exciting pick for investors as it is poised to beat at earnings season.
KPTI: 7.51 (-0.52)

Quanta Services (PWR) Q1 Earnings: Will It Disappoint?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 3:52PM CDT
Quanta Services (PWR) is expected to report first-quarter 2016 results on May 5. Let's see how things are shaping up for this announcement.
PWR: 23.21 (-0.90), PEGI: 22.00 (-0.84), AMID: 12.41 (+0.09), KPTI: 7.51 (-0.52)

Match Group (MTCH) Q1 Earnings Preview: What to Expect
Zacks Equity Research - Zacks Investment Research - Mon May 02, 6:04PM CDT
Match Group (MTCH) is set to report first-quarter 2016 earnings results after the closing bell on May 3. Let's see how things are shaping up for this announcement.
MTCH: 14.79 (-0.81), PEGI: 22.00 (-0.84), AMID: 12.41 (+0.09), KPTI: 7.51 (-0.52)

Karyopharm to Report First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Mon May 02, 7:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2016 financial results and provide a company update on Monday, May 9, 2016. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, May 9, 2016 to discuss the financial results and recent business developments.
KPTI: 7.51 (-0.52)

Karyopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1) Inhibition in the Treatment of Traumatic Brain Injury
GlobeNewswire - Wed Apr 20, 6:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced preclinical data demonstrating the activity of its Selective Inhibitor of Nuclear Export (SINE) compound, KPT-350, in rodent models of traumatic brain injury (TBI). These data were presented at the 2016 Annual Meeting of the American Academy of Neurology (AAN) taking place April 15-21 in Vancouver, Canada.
KPTI: 7.51 (-0.52)

Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 2.14 (-0.22), OMER: 10.36 (-0.62), ATHX: 1.94 (-0.06), KPTI: 7.51 (-0.52), CUR: 0.28 (-0.01)

Karyopharm Taps TransPerfect as eTMF and Functional TMF Provider
PR Newswire - Wed Apr 06, 9:00AM CDT
TransPerfect, a leading provider of global development and commercialization solutions to the life sciences industry, today announced that Karyopharm Therapeutics has implemented Trial Interactive as its electronic Trial Master File (eTMF).
KPTI: 7.51 (-0.52)

Karyopharm to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the upcoming 15 Annual Needham Healthcare Conference in New York City on Tuesday, April 12, 2016 at 8:40 a.m. ET.
KPTI: 7.51 (-0.52)

Karyopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus
GlobeNewswire - Thu Mar 31, 7:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has been awarded a grant from the National Institute of Allergy and Infectious Disease (NIAID) to advance development of KPT-350, an oral Selective Inhibitor of Nuclear Export / SINE(TM) compound for the treatment of inflammatory, autoimmune and neurological diseases. The $225,000 grant will be used to conduct further preclinical studies of KPT-350 for the treatment of systemic lupus erythematosus, or lupus, a chronic, autoimmune disease that causes the body to create autoantibodies that attack and destroy healthy tissue, causing inflammation, pain, and damage in various parts of the body. These studies will be conducted in collaboration with Dr. Jenifer Anolik, MD, PhD, Associate Professor of Medicine at the University of Rochester.
KPTI: 7.51 (-0.52)

Karyopharm to Present Data on Oncology Pipeline at the 2016 American Association for Cancer Research Annual Meeting
GlobeNewswire - Wed Mar 16, 4:00PM CDT
Two Late-Breaking Posters Featuring the Company's Lead Drug Candidate, Selinexor (KPT-330), and Second Generation SINE Compound KPT-8602
KPTI: 7.51 (-0.52)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Poker Fans Flock to Venom PKOs and WSOP Paradise

October's High Stakes Poker Action The poker buzz right now is centered around Americas Cardroom. With $5.5 million in guarantees across two major tournaments – the No-Limit Hold'em and Pot-Limit Omaha – players are reaching for their cash, hoping to lock in big wins. Day 1B kicks off today, offering a dynamic mix of players vying for their shot at glory while taking...

Caitlyn Brazill Takes Helm at Per Scholas: CEO Transition

Caitlyn Brazill named CEO, marking a leadership shift Call this one a big baton pass in the world of workforce development. Caitlyn Brazill is stepping into the role of CEO and President at Per Scholas, effective January 1, 2027. She'll be filling the rather large shoes of Plinio Ayala, the man who's been steering the ship since its days in the Bronx, growing it into a...

Teamsters Secure Landmark Deal for SF Parking Workers

Major Win for San Francisco's Parking Professionals Parking lots and garages across San Francisco might not be the first places you’d look for labor triumphs, but that’s exactly what almost 1,000 members of Teamsters Local 665 have achieved. Under a newly ratified four-year master contract, these parking pros snagged one of the richest deals the industry has seen. A...

Protecting Your Family on Halloween: Safety Tips

Avoid Turning Halloween Fun Into a Medical Emergency Halloween should be about ghosts and ghouls, not a dreaded detour to the ER. Yet, every year, adults and kids get carried away with costumes, only to find themselves in a real-life horror show courtesy of a slip, a fall, or a carving mishap. The American Academy of Orthopaedic Surgeons (AAOS) is waving the safety flag,...

Elevest Unveils MADE: Shaping Wealth for Athletes, Artists

Turning Talent Into Tangible Wealth Ask any musician or athlete, and they'll tell you—riding those career highs is exhilarating, but financial stability can be a different ballgame. Here comes Elevest Capital with a fresh move meant to set the players right where many falter: long-term ownership. They're rolling out MADE, a new initiative focused on flipping that burst...

Icebox Takes on Buckhead with Diamonds and Discounts

So, Atlanta's Icebox Diamonds & Watches just dropped a news bomb that could shake up anyone with a taste for glitz and a wallet ready to act. This iconic jeweler, swinging its roots from a humble family biz to a global gem, is opening up its vault with an Inventory Reduction Sale starting October 9. And folks, it’s happening right at their Buckhead flagship showroom....

Rutter Mills Secures $13M in Virginia Injury Cases

The Stakes in Virginia When you drop nine successful injury cases on the scales and they tip over $13 million, that's a story worth dissecting. The two top dogs at Rutter Mills certainly know how to make a splash in the legal puddle, don't they? We're talking about attorneys Adam H. Lotkin and Georgina D. Montgomery here, the legal eagles behind these jaw-dropping...

PrideStaff: 8 Years Strong on Franchise Times Top 400

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

DIFF Eyewear Opens First Flagship Store in Charleston

DIFF Eyewear: From Clicks to Bricks in Charleston Here's a tale of a brand shaking things up, jumping from the digital stratosphere right into solid ground. DIFF Eyewear has officially planted its flag in Charleston, SC, marking a bold transition from being an exclusively online player to real-world retail. October 10th rang in their first brick-and-mortar store on...

CellFiber Expands to Philly: Boosting US Biotech Scene

CellFiber's Leap into 'Cellicon Valley' Folks, when the biotech winds start blowing, you better have your sails up. CellFiber Co., Ltd., a Tokyo-based innovator, has landed itself a comfy spot in the City of Brotherly Love. We're talking Philadelphia, folks, or, as it's dubbed in certain circles, 'Cellicon Valley.' Now if that's not a name that screams biotech pedigree, I...